Equal-WT
WhaleScore 2.0
?
BVF is based out of San Francisco. BVF is a hedge fund with 5 clients and discretionary assets under management (AUM) of $6,146,999,398 (Form ADV from 2024-03-29). Their last reported 13F filing for Q4 2024 included $2,950,707,648 in managed 13F securities
and a top 10 holdings concentration of 70.08%. BVF's largest holding is MoonLake Immunotherapeutics with shares held of 19,751,284. Whalewisdom has at least 97 13F filings
Business Description
BVF Partners L.P. (“BVF” or “we”) is an asset management firm that generally invests in biotechnology companies. BVF is a Delaware limited partnership that commenced operations.
BVF currently provides investment advice to the BVF Funds, the Single Investor Fund and the Managed Accounts.
Investment Strategy
BVF primarily focuses on long equity investing in small-capitalization companies, particularly within the biotechnology sector. This strategy is speculative and highly issuer-specific, making it susceptible to mismanagement, misconduct, subjective investment factors, and market sentiment.
BVF adopts a selective stock-picking strategy within the biotechnology industry, resulting in an undiversified portfolio. While they aim to identify issuers with limited downside risk relative to upside opportunity, investors should anticipate substantial volatility and potential losses. BVF faces competition from other investment management firms, many of which have greater resources, which is significant given BVF’s emphasis on resource-intensive fundamental analysis.
Owners
- BVF INC. - GENERAL PARTNER
- LAMPERT, MARK, NATHAN - CHIEF EXECUTIVE OFFICER
- MCCUNE, JASON, ROBERT - CHIEF OPERATING OFFICER
- KRATKY, JAMES, GEOFFREY - CHIEF FINANCIAL OFFICER, CHIEF COMPLIANCE OFFICER Click on the Ownership/Private Fund Data tab for more details.
Other Contact Information
(Subscription Required)
2024-12-31
Top Buys (13F)
| Name | % Change |
|---|---|
| SEPN Septerna Inc | 1.9% |
| RVMD Revolution Medicines | 1.58% |
| XNCR Xencor Inc | 1.28% |
| AXSM Axsome Therapeutics | 1.23% |
| VERV Verve Therapeutics I | 1.23% |
2024-12-31
Top Sells (13F)
| Name | % Change |
|---|---|
| OLMA Olema Pharmaceutical | 2.06% |
| FDMT 4D Molecular Therape | 1.83% |
| IONS Ionis Pharmaceutical | 1.7% |
| TYRA Tyra Biosciences Inc | 1.35% |
| IDYA Ideaya Biosciences I | 1.31% |
2024-12-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| MLTX MoonLake Immunothera | 36.25% |
| KYMR Kymera Therapeutics, | 7.04% |
| RVMD Revolution Medicines | 6.2% |
| AXSM Axsome Therapeutics | 3.98% |
| MIRM Mirum Pharmaceutical | 3.92% |
2024-12-31
13F Activity
| Market Value | $2.95b, Prior: $3.42b |
| Inflows (Outflows) as % of Total MV | (-4.1863)% |
| New Purchases | 4 stocks |
| Added To | 11 stocks |
| Sold out of | 6 stocks |
| Reduced holdings in | 13 stocks |
| Top 10 Holdings % | 70.08% |
| Turnover %[1] | 16.95% |
| Turnover Alt %[2] | 9.19% |
| Time Held Top 20 | 5.75 quarters |
| Time Held Top 10 | 3.1 quarters |
| Time Held All | 11.6 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-12-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-12-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-12-31